Carlos A. MorilloJosé Antônio Marin‐NetoÁlvaro AvezumSergio Sosa‐EstániAnis RassiFernando RosasErick VillenaRoberto QuirozRina BonillaConstança Britto2026-03-222026-03-22201510.1056/nejmoa1507574https://doi.org/10.1056/nejmoa1507574https://andeanlibrary.org/handle/123456789/42983Citaciones: 1009Trypanocidal therapy with benznidazole in patients with established Chagas' cardiomyopathy significantly reduced serum parasite detection but did not significantly reduce cardiac clinical deterioration through 5 years of follow-up. (Funded by the Population Health Research Institute and others; ClinicalTrials.gov number, NCT00123916; Current Controlled Trials number, ISRCTN13967269.).enBenznidazoleMedicineInternal medicinePlaceboHazard ratioOdds ratioChagas diseaseCardiomyopathyHeart transplantationHeart failurearticle